Tysabri natalizumab: Phase III data

In the double-blind, placebo-controlled Phase III ENACT-1 trial in 905 patients, Tysabri missed the primary and secondary endpoints. The Tysabri group had a 56% response rate vs. 49% with placebo (p=0...